1 2 3 4 Effects of varenicline and cognitive bias modification on neural response to 5 smoking-related cues: a randomised control trial 6 7 Abstract 44 Drug-related cognitive biases have been positively associated with drug-craving and 45 increased likelihood of relapse. Cognitive bias modification paradigms have been 46 developed to attenuate cognitive biases but there have been few studies that 47 examined neural responses to these paradigms. This study compared neural 48 responses following CBM and explored whether CBM effects were potentiated by 49 varenicline administration. This was a double-blind placebo-controlled study with two 50 between subject factors of drug (varenicline, placebo) and CBM (attend towards 51 smoking cues, train away from smoking cues, control training) that recruited daily (> 10 52 cigarettes per day) non-treatment seeking smokers. Participants (n = 67, 53% female)
age, fluent in English and registered with a General Practitioner. Exclusion criteria 151 were pregnancy, breast feeding or at risk of pregnancy (i.e., females not using 152 adequate contraception), substance misuse, high alcohol consumption (>35 153 units/week if female or >50 units/week if male) or caffeine consumption (> 8 cups of 154 caffeinated beverage per day), current or past psychiatric disorder, clinically 155 significant abnormality (including cardiology risk factors), use of medication 156 (participants were required to be 8 weeks clear of any prescribed medication), 157 known hypersensitivity to varenicline, high blood pressure or heart rate 158 (systolic/diastolic >140/90 mmHg or heart rate >90 bpm), uncorrected visual or 159 auditory impairment, and any condition that would make MRI scanning unsafe (e.g.,
160
metallic implants) or intolerable. The study was approved by the National Research
161
Ethics Service (London Brent Committee, reference: 11/LO/1726). All participants 162 gave written informed consent and were reimbursed £70 at the end of the study. This was a double-blind, placebo-controlled study that used a 2 × 3 between-166 subjects design, comprising one factor of drug (varenicline, placebo) and one factor 167 of CBM group (attend, avoid, control) . For the behavioural assessments of cognitive 168 bias (dot probe, modified Stroop), there was an additional within-subjects factor of 169 cue type (smoking, neutral).
171
Drug administration
172
Following initial consent and screening on day 0, varenicline (or matched 173 placebo) was prescribed by a medical doctor for one week. Participants were told to 174 take one tablet (0.5 mg) daily on days 1 -3, two tablets daily (total 1 mg) on days 4 -175 6, and one tablet (0.5 mg) on day 7, consistent with standard dosing regimen for 176 smoking cessation. Participants completed daily diaries detailing the time at which 177 the tablets were taken and any side effects. Participants attended their second Running head: Varenicline, cognitive bias modification and fMRI in smokers 8 session on day 7 (i.e., their last drug day) and were asked to take the drug in the 179 morning prior to their study session.
181
Randomisation 182 Participants were randomly assigned to drug and CBM groups (stratified by 183 gender), but equal numbers of participants per group were maintained. Drugs were 184 supplied by Pfizer and shipped to University Hospitals Bristol Pharmacy who 185 prepared two batches of 36 bottles (one for male and one for females). Within each 186 group of 36 bottles, 18 bottles contained 10 varenicline tablets (0.5 mg each) and 18 187 bottles contained 10 tablets of matched placebo. Each bottle was given a numeric 188 identifier that enabled study staff involved in data collection to be fully blinded to 189 drug condition.
190
In addition, an experimental collaborator (who had no direct contact with the 191 study participants) prepared a numeric code using random number assignment 192 software to further randomise participants to CBM groups. Randomisation was 193 stratified so that equal numbers of male and female participants (n = 12) were category. The set of cues pictures is the same as used in previous imaging studies 203 (McClernon, Kozink, Lutz, & Rose, 2009; McClernon, Kozink, & Rose, 2008) . For the 204 cognitive bias modification task, an additional 4 picture pairs, unrelated to smoking, 205 were used in practice and buffer trials.
Cognitive Bias Modification:
Participants were randomised to complete a 207 modified visual dot probe task designed to induce a biased cognitive response away 208 from (avoid: n = 24), or towards (attend: n = 24) smoking-related cues, or a control 209 condition (control: n = 24). Each task version comprised 768 trials. Each trial began 210 with a fixation cross (500 ms), before a picture pair (smoking image, neutral image) 211 was presented on a computer screen. The picture pair stayed on screen for 500 ms 212 and then was replaced by a probe (small square or circle) in a location previously 213 occupied by one of the pictures. Participants were required to identity whether the 214 probe was a square or circle by pressing designated keyboard keys.
215
The majority of trials (n = 512) were training trials, presented in four blocks, 216 and the remainder of trials (n = 256) were test trials. Half of the test trials (n = 128)
217
were presented prior to the training trials (baseline test), and half (n = 128) after the 218 training trials, in order to assess the effect of the CBM on cognitive bias. In the test 219 trials, the probe appeared with equal frequency in the location of the smoking-related 220 or neutral picture. In the training trials, the probe appeared in the location of the press on each stimulus presentation to confirm they had seen the image (this did not 249 terminate viewing time). Each block lasted 40 s, during which time 8 cues were 250 presented. Before and after each block, a crosshair was presented for 5 s.
251
Participants were then asked to rate cigarette craving on an 8-point scale ("none at 252 all" to "extreme"). The scale was presented for 10 s followed by a crosshair for 253 another 10 s. Thus, the total interblock-interval was 25 s. The sequence of events 254 was controlled using EPrime version 2 software (Psychology Software Tools Inc.,
255
Pittsburgh PA), and total task time was approximately 10 min.
257
Procedure
258
Individuals who responded to study advertisements were sent the full 259 information sheet and completed a telephone screening to assess basic eligibility.
260
Eligible participants were then booked in for a screening and baseline assessment session (Day 0). At this session full written informed consent was taken by a trained 262 researcher, and then the screening procedure was completed. This included 263 measures of expired breath alcohol and carbon monoxide, height, weight, blood 264 pressure and heart rate. A urine screen was performed to test for recent drug use 265 (all) and pregnancy (females). A medical doctor then completed a general physical 266 and psychiatric health assessment, and prescribed the study medication if 267 appropriate. Then participants completed a baseline assessment of cognitive bias 268 (modified Stroop), questionnaires assessing personality (EPQ-R), cigarette craving 269 and withdrawal (QSU, MNWS) and mood (VASs), and a practice version of the task 270 that they would completed during the fMRI scan at the second visit (Day 7).
271
Participants were then sent away with the study medication, medication 272 packaging information and a drug diary (which they were required to complete and 273 return at the next visit). The second session (test day) was then scheduled for 274 approximately one week later. This session fell on day 7 of their drug regimen.
275
On the test day (Day 7), participants returned with their drug diaries and any 276 untaken medication. Prior to the scan, they completed the Stroop task followed by a 277 short visual dot probe task that measured baseline cognitive bias. Participants then 278 completed one version of CBM (avoid, attend, control) per the study randomisation.
279
The test version of the dot-probe task was run again immediately post-CBM in order 280 to assess changes in cognitive bias. Following this, participants completed a 4- 
389
For error data, three participants were identified as outliers in the pre-CBM 390 condition and one participant was identified as an outlier in the post-CBM condition.
391
These data were removed from main analysis. After data removal error data were not 392 normally distributed and a square root transformation was applied to these data.
393
There was weak evidence of a drug × CBM interaction (F [1, 57] = 2.74, p =
394
.073, ηp 2 = .09) for errors, reflecting a bias towards smoking (versus neutral) cues in 
408
Tonic craving across drug treatment: For QSU data, there was evidence of 409 effects of time (F [1,65] = 33.61, p < .001, ηp 2 = .34) and drug (F [1,65] = 6.06, p = .017, 410 ηp 2 = .09), which were subsumed under a time × drug interaction (F [1,65] = 4.37, p = 0.04, ηp 2 = .06). Post-hoc paired samples t-tests showed that there was a decrease in 412 craving from session one (pre-drug) to session two (post-drug) in both drug groups, but 413 this effect was larger in the varenicline group (see Table 2 
420
.078, ηp 2 = .05) and irritability (F [1,62] = 8.56, p = .005 ηp 2 = .12), with decreases in 421 happiness, and increases in drowsiness, depression, anxiety and irritability. There was 422 also evidence of an effect of drug for anxiety (F [1,62] = 9.01, p = .004, ηp 2 = .13), with 423 lower anxiety reported in the varenicline group. There was no clear evidence of any 424 other main effects or interactions (ps >.10). 
426

511
training would reverse such effects is unclear from the data, which suggests that 512 additional research is needed to fully understand the influence of CBM on the 513 processing of smoking cues.
514
Taken together these findings support a benefit of varenicline on tonic craving 515 and neural response to smoking cues (which may be driven by the craving effects).
516
While the effects of varenicline may be small, they are meaningful given the fact that 517 the dosing regime delivered in the study is substantially lower than the clinically 518 prescribed dose (i.e., 1 week compared to a standard 12-week course). However, we 519 found no evidence of a benefit of CBM on any outcomes, and little evidence that 520 varenicline would be a useful adjunct to smoking-related CBM. The CBM by drug 521 interaction that was observed for the fMRI data, indicated that the effects of varenicline 522 may have been attenuated for active CBM (i.e., the effects were only observed in the 523 control training group). However, numbers are small and therefore this effect requires 524 replication.
525
It is noteworthy that we did not find effects of CBM on measures of cognitive 526 bias (visual dot probe and Stroop). There are known issues with the reliability of 527 cognitive bias tests (Ataya et al., 2012) , and therefore this may be a failure of the 528 measure rather than a lack of effect. However, this indicates that the CBM may not 529 have been effective, and these findings should be interpreted with this in mind. We 530 hypothesised that effects of CBM would be potentiated by varenicline and our failure to 531 observe such effects may be due to there being no CBM effects to strengthen. It is 532 plausible that varenicline may potential effects of CBM if these effects can be reliably 533 achieved.
534
There are some limitations of this study that should be considered when 535 interpreting these findings. First, our sample size was small for the analysis of 536 interactions. Our planned recruitment of 72 participants was achieved but not all 537 participants were tested to completion, and our final sample was lower (n = 67 for subjective and cognitive data; n = 64 for fMRI data). We also have a computer 539 malfunction for one of the conditions that was not identified until data were extracted.
540
We had to replace a number of participants in one CBM condition (avoid) and therefore 541 these individuals were tested outside of the randomisation sequence. We do not 542 however expect that this had a substantial effect on outcomes as these individuals 543 were testing in close time proximity to the rest of the sample. Furthermore, the 544 researchers collecting data were not aware of the reason for additional recruitment,
545
and therefore double-blinding was maintained. Third, our study recruited non-treatment 546 seeking smokers, and it is plausible that effects of CBM may be stronger in individuals 547 seeking treatment.
548
This study investigated neural responses to smoking cues following varenicline 549 and CBM treatment. There was little evidence of neural effects of either drug or CBM.
550
However, there was evidence of reductions in craving among smokers who completed 551 one-week of varenicline treatment. Drug by CBM interactions were exploratory due to 552 small sample sizes, but we observed an interaction on right temporal gyrus activity.
553
Specifically, varenicline appeared to attenuate cue-related activity in the right temporal 554 gyrus that was presented in the placebo group. However, this effect should be 555 replicated in future research. In summary, this study finds little evidence of clinical 556 potential of CBM. 557 558
